4//SEC Filing
Poole William 4
Accession 0001181431-05-050788
CIK 0001103021other
Filed
Sep 6, 8:00 PM ET
Accepted
Sep 7, 6:28 PM ET
Size
7.9 KB
Accession
0001181431-05-050788
Insider Transaction Report
Form 4
Poole William
Director
Transactions
- Award
Option
2005-07-28−35,000→ 35,000 totalExercise: $2.94From: 2005-07-28Exp: 2015-07-28→ Common Stock (35,000 underlying)
Holdings
- 3,190
Series A Preferred
Exercise: $4.25→ Common Stock (3,190 underlying)
Footnotes (3)
- [F1]One share of common stock for one share of preferred stock
- [F2]The Series A Preferred will be convertible into shares of the Company's common stock ( the "Common Stock") on a one for one basis. The Series A Preferred is eligible for conversion upon the earlier to occur of: (i) FDA approval of Arius' first proposed product (ii) 30 days notice to the Company of a Conversion Event (hereinafter defined) or (iii) five years from the closing date of the Transaction. The term "Conversion Event" is defined in the Certificate of Designation of the Series A Preferred to mean the failure of the Company to provide at least $3,000,000 to Arius as required to: (i) pay Atrix Laboratories, Inc. ("Atrix") $1,000,000 by August 24, 2004 pursuant to the terms of a license agreement between Arius and Atrix and (ii) fund, in a total amount of no less than $2,000,000, the operations of Arius.
- [F3]Not applicable
Documents
Issuer
BIODELIVERY SCIENCES INTERNATIONAL INC
CIK 0001103021
Entity typeother
Related Parties
1- filerCIK 0001326017
Filing Metadata
- Form type
- 4
- Filed
- Sep 6, 8:00 PM ET
- Accepted
- Sep 7, 6:28 PM ET
- Size
- 7.9 KB